In the global healthcare sector, UnitedHealth Group and Eli Lilly & Company are two powerful giants. UnitedHealth Group (UNH), a comprehensive healthcare behemoth, provides insurance, medical services, and technology solutions to millions of customers. Meanwhile, Eli Lilly (LLY) is a leader in the pharmaceutical industry. With its strengths in hot areas like anti-obesity drugs, its market capitalization has surpassed one trillion dollars, making it the world’s most valuable healthcare company by market cap. However, the two companies’ market performances in 2025 were diametrically opposed, prompting investors to delve deeper into their investment potential for 2026.
UnitedHealth Group’s stock price experienced a significant decline in 2025, falling nearly 35%. This trend began with the tragic killing of its insurance business CEO last December, followed by the company being investigated for alleged fraud and misconduct related to billing practices. Additionally, unexpected cost surges in businesses like Medicare severely impacted its earnings performance for the year.
To address these challenges, management is actively implementing adjustment measures, including substantially raising premiums for next year and even exiting certain markets if necessary. The company anticipates that these moves could lead to a loss of up to one million enrollees in its Medicare Advantage plans. However, they are also aimed at enhancing the long-term profitability of the business. Despite facing short-term pain, UnitedHealth Group’s core position within the US healthcare system remains solid. Its current forward P/E ratio based on expected earnings is approximately 21, presenting a potential entry point for long-term investors.
In contrast to UnitedHealth Group, Eli Lilly’s stock price surged nearly 35% in 2025. This is primarily attributed to its leading position in the high-growth anti-obesity drug market. This market is projected to soar from $15 billion to $150 billion in sales over the next decade, and Lilly, along with its main competitor Novo Nordisk, currently dominates the field. Over the past 18 months, Lilly has continued to gain market share while maintaining robust revenue growth, with a year-over-year increase of 54% in the third quarter.
Lilly’s research and development pipeline also holds significant potential. Its oral weight-loss drug, orforglipron, and a new injectable, retatrutide, are both in Phase 3 clinical trials and are expected to contribute meaningfully to the company’s growth over the next five to ten years. Despite its lofty valuation, with a forward P/E ratio as high as 45, analysts project its annual earnings growth rate over the next three to five years could reach 37%, reflecting strong growth expectations.
From an investment perspective, UnitedHealth Group and Eli Lilly present different risks and opportunities. UnitedHealth Group’s management anticipates that as premium adjustment measures take effect, the company’s earnings will return to growth in 2026 and accelerate in 2027. Analysts forecast its average annual growth rate over the next three to five years could be between 9% and 10%, but this is contingent on the company not encountering new major operational setbacks.
Eli Lilly, with its advantageous position in the anti-obesity drug market and a rich R&D pipeline, exhibits clearer and stronger growth momentum. UnitedHealth Group, on the other hand, must first overcome its current operational and regulatory challenges to more fully unlock its long-term value.
